Journal Guide
Publishing in JAMA Cardiology: Fit, Timeline & Submission Guide
JAMA Cardiology doesn't want basic science dressed up as clinical relevance. It wants studies that will change what cardiologists do Monday morning. If your trial won't alter treatment guidelines or clinical decision-making, you're submitting to the wrong journal.
Should you submit here?
Submit if jAMA Cardiology prioritizes trials that will influence guidelines or change what physicians do. Be careful if jAMA Cardiology sees too many papers where authors equate a reduction in LDL cholesterol or blood pressure with reduced cardiovascular events.
Best fit if
JAMA Cardiology prioritizes trials that will influence guidelines or change what physicians do
Not ideal if
JAMA Cardiology sees too many papers where authors equate a reduction in LDL cholesterol or blood pressure with reduced cardiovascular events
Also compare
15.6
Impact Factor (2024)
~8%
Acceptance Rate
14-21 days to first decision
Time to First Decision
Submission guide
JAMA Cardiology Submission Guide
A practical JAMA Cardiology submission guide focused on clinical importance, broad-readership fit, and package readiness before upload.
Journal assessment
Is JAMA Cardiology a Good Journal? The JAMA Network's Cardiovascular Title
JAMA Cardiology (IF 14.1) is the JAMA Network's cardiovascular journal. Here's when it's the right target, how the JAMA transfer pipeline works, and how it compares to JACC, Circulation, and EHJ.
Desk rejection
How to Avoid Desk Rejection at JAMA Cardiology
Practical guidance on how to avoid desk rejection at JAMA Cardiology, including what editors screen for first and where strong papers usually fail.
What JAMA Cardiology Publishes
JAMA Cardiology focuses on original clinical research that directly informs cardiovascular practice. That sounds obvious, but here's what it means in practice: editors want papers where the clinical implications are immediate and specific, not theoretical or distant. They're not interested in mechanistic studies unless those mechanisms directly explain why a treatment works or fails in patients. The journal covers the full spectrum of cardiovascular medicine, from prevention to intervention to outcomes, but there's a heavy bias toward randomized controlled trials, large observational cohort studies, and systematic reviews that synthesize actionable evidence. If you're doing translational work, you'll need a clear path to the bedside, not just promising preclinical data.
- Randomized controlled trials testing cardiovascular interventions, devices, or drug therapies with clinically meaningful endpoints like mortality, hospitalization, or major adverse cardiac events.
- Large observational studies using registries, claims data, or cohort databases that reveal practice patterns, outcomes disparities, or risk factors relevant to real-world patient populations.
- Secondary analyses of major trials that answer clinically important questions the original study wasn't powered to address, provided the analysis plan is rigorous and prespecified.
- Systematic reviews and meta-analyses that synthesize evidence on treatment decisions where practice varies or guidelines are uncertain, with GRADE-quality evidence assessment.
- Health policy research examining cardiovascular care delivery, cost-effectiveness, or healthcare system factors that influence patient outcomes at scale.
Editor Insight
“I'll be direct about what we're looking for. Every submission I review, I ask myself: will this change what cardiologists do tomorrow? If the answer is 'maybe in five years' or 'for a small subset of patients,' that's usually not enough. We get papers from excellent research groups with perfect methodology, but the clinical question just isn't pressing. Those get rejected. What I want to see is a paper where I can immediately envision the guideline committee citing it, or a practicing cardiologist changing their approach. I desk-reject a lot of well-written papers that belong in specialty journals because they're too narrow. On the other hand, we're quite receptive to negative trials that answer important questions, large registry studies revealing practice gaps, and papers addressing health disparities. Don't assume we only want positive results. We want truth that matters.”
What JAMA Cardiology Editors Look For
Practice-changing clinical trials
JAMA Cardiology prioritizes trials that will influence guidelines or change what physicians do. This means you need clinically meaningful primary endpoints, not just statistically significant biomarker changes. A trial showing a 15% relative reduction in a surrogate marker won't cut it unless that marker is strongly validated. The editors want to see hard endpoints: death, myocardial infarction, stroke, heart failure hospitalization. If you're using a composite endpoint, each component should be clinically important on its own.
Rigorous methodology with transparent reporting
The journal follows CONSORT, STROBE, and PRISMA guidelines strictly. Don't submit unless you've completed the relevant checklist and can provide it. Editors desk-reject papers where the methods section doesn't allow replication or where key details are buried in supplementary materials. They want the randomization scheme, blinding procedures, and sample size calculation front and center. If you're doing an observational study, you'll need a clear description of how you handled confounding and selection bias.
Global relevance with diverse patient populations
There's increasing scrutiny of whether trial populations reflect the patients who'll actually receive the treatment. If your RCT enrolled mostly white men from academic medical centers, you'll need to address generalizability explicitly. The editors value studies that include underrepresented populations or that specifically examine whether treatment effects differ by race, sex, or socioeconomic status. Single-center studies from specialty referral centers face a higher bar than multicenter trials with community hospital sites.
Clear clinical implications stated directly
Your discussion section shouldn't require readers to infer the clinical implications. State them explicitly. What should change in practice based on your findings? Which patients benefit most? What's the number needed to treat? Editors reject papers where authors hedge so much that the clinical message gets lost. They want you to be appropriately confident about what your data show while being honest about limitations. Don't oversell, but don't undersell either.
Novel findings that fill evidence gaps
The journal doesn't need another paper confirming what we already know. Before submitting, ask: does this change our understanding or just reinforce it? Editors want papers that address questions where current evidence is weak, conflicting, or nonexistent. If you're studying a topic with 50 prior meta-analyses, you'd better have a genuinely new angle, new population, or new outcome. Incremental advances belong in specialty journals.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past JAMA Cardiology's editorial review:
Submitting surrogate endpoint studies as if they're definitive
JAMA Cardiology sees too many papers where authors equate a reduction in LDL cholesterol or blood pressure with reduced cardiovascular events. The editors understand that surrogate endpoints can inform mechanism and generate hypotheses, but they won't accept these studies unless the surrogate is well-validated and the clinical context makes the findings immediately actionable. If your primary outcome is a biomarker, you need to make a compelling case for why physicians should care now, not after another decade of outcomes trials.
Overstating the novelty of observational findings
Large database studies that confirm associations already established in RCTs don't add much. The editors see dozens of papers showing that smoking causes cardiovascular disease or that statins reduce events. Unless your observational study reveals something we couldn't learn from trials, like rare events, long-term outcomes, or real-world effectiveness versus efficacy, it won't survive initial review. You need to articulate what your observational design uniquely contributes.
Burying methodological problems in limitations sections
Experienced reviewers and editors know what to look for. If your trial had differential dropout, your observational study has residual confounding, or your meta-analysis combined heterogeneous interventions, acknowledging these in the limitations paragraph won't save you. Address these issues in the methods and results, showing how you handled them analytically. A limitations section isn't a confessional, it's a place for irreducible uncertainties, not fixable design flaws.
Writing for specialists in your subfield only
JAMA Cardiology's readership includes general cardiologists, internists, and cardiac surgeons across subspecialties. If your paper assumes familiarity with interventional cardiology jargon, electrophysiology techniques, or advanced imaging physics, you'll lose most readers. The editors want accessible prose that communicates findings to any physician. This doesn't mean dumbing down your science. It means explaining technical concepts briefly and focusing on what matters clinically.
Neglecting the 'so what' factor in the abstract
Many manuscripts get desk-rejected based on the abstract alone. Editors need to see, in 350 words or less, what question you asked, how you answered it rigorously, what you found, and why it matters for patient care. Abstracts that read like technical summaries without clinical context don't make the cut. Your conclusions should tell a busy clinician exactly what's actionable. Don't make them read the full paper to understand why they should care.
Does your manuscript avoid these patterns?
The Free Readiness Scan reads your full manuscript against JAMA Cardiology's criteria and flags the specific issues most likely to cause rejection.
Insider Tips from JAMA Cardiology Authors
Reference ongoing guidelines debates explicitly
If your paper addresses a question where ACC/AHA guidelines are uncertain or where practice varies by region, say so in your introduction. Editors prioritize papers that inform active guideline discussions. Knowing that the next guideline update is considering your intervention makes your paper more timely and relevant.
Preregistration is increasingly expected
For clinical trials, ClinicalTrials.gov registration is mandatory. But even for observational studies and systematic reviews, preregistration on platforms like PROSPERO or OSF signals rigor. Editors are more skeptical of unregistered studies, especially secondary analyses where outcome switching is easy to hide.
Consider submitting a Research Letter for important negative findings
Null results from well-designed trials still matter for clinical practice. If your trial didn't show benefit, it might fit better as a 600-word Research Letter than a full article. Editors appreciate brevity for findings that mainly update priors rather than generate new paradigms.
Include health economists or outcomes researchers as co-authors
Papers that address cost, value, or implementation alongside efficacy are increasingly favored. If you can show that your intervention is not only effective but also cost-effective or feasible to implement in resource-limited settings, you're more likely to get accepted. Clinician-only author lists sometimes signal a narrow focus.
The cover letter matters more than you think
Editors at JAMA Cardiology receive hundreds of submissions monthly. A well-crafted cover letter that explains why your paper fits the journal, what's novel, and what the clinical implications are can determine whether you get a fair review or a desk rejection. Don't just restate your abstract, sell the paper.
The JAMA Cardiology Submission Process
Prepare manuscript according to JAMA Network formatting
1-2 weeks before submissionFollow JAMA Network author instructions precisely, including structured abstract format, word limits, and reference style. JAMA Cardiology has specific requirements for trials, observational studies, and reviews. Missing elements like conflict of interest disclosures or author contribution statements will delay processing.
Complete relevant reporting checklist
During manuscript preparationCONSORT for RCTs, STROBE for observational studies, PRISMA for systematic reviews. Upload the completed checklist with your submission. Incomplete checklists result in administrative rejection before editorial review begins.
Submit via JAMA Network manuscript submission system
Day of submissionCreate an account or log in to the JAMA Network ScholarOne portal. Enter all co-author information, including ORCID identifiers. Upload your manuscript, figures, tables, supplementary materials, and cover letter as separate files according to specifications.
Editorial triage and initial decision
7-14 daysAn editor reviews your submission for fit, novelty, and methodological rigor. About 60% of submissions are desk-rejected at this stage, typically within 7-14 days. If your paper passes triage, it enters peer review.
Peer review process
4-8 weeksTwo to three external reviewers with relevant expertise evaluate your manuscript. They assess methodology, interpretation, and clinical relevance. Reviewers provide detailed comments and recommendations to the editor, who makes the final decision.
Decision and revision
2-4 weeks for revision, 2-4 weeks for re-reviewYou'll receive accept, minor revision, major revision, or reject. Most accepted papers require revision. Address every reviewer comment point-by-point in your response letter. Be thorough but concise. Revised manuscripts undergo re-review, usually by the original reviewers.
JAMA Cardiology by the Numbers
| 2024 Impact Factor(Consistently among top 5 cardiovascular journals) | 15.6 |
| Acceptance Rate(High selectivity means most submissions are rejected editorially) | ~8% |
| Time to First Decision(Fast editorial triage, longer for full peer review) | 14-21 days |
| Time to Publication(From acceptance to online publication) | 3-6 months |
| Altmetric Score (median)(High media attention for published articles) | >100 |
| Open Access Option(CC-BY license, approximately $5,000 APC) | Available |
Before you submit
JAMA Cardiology accepts a small fraction of submissions. Make your attempt count.
Start with the Free Readiness Scan. Unlock the Full AI Diagnostic for $29. If you need deeper scientific feedback, choose Expert Review. The full report is calibrated to JAMA Cardiology.
Article Types
Original Investigation
3,000 wordsFull-length research articles reporting primary data from clinical trials, observational studies, or secondary analyses. Must include structured abstract and follow relevant reporting guidelines.
Research Letter
600 words, 1 figure/tableBrief reports of preliminary findings, important negative results, or focused observations. Useful for timely communication of smaller but significant datasets.
Review
4,000 wordsInvited or commissioned systematic reviews and clinical reviews synthesizing evidence on important topics. Most reviews are solicited by editors, but queries are welcome.
Viewpoint
1,200 wordsOpinion pieces on clinical practice, health policy, or controversies in cardiovascular medicine. Should present a clear argument with supporting evidence.
Editorial
1,000 wordsInvited commentaries accompanying published articles. Provide context, interpretation, and implications for the featured research.
Landmark JAMA Cardiology Papers
Papers that defined fields and changed science:
- Solomon et al., 2019 - Reported results of PARAGON-HF trial testing sacubitril/valsartan in heart failure with preserved ejection fraction
- Bhatt et al., 2020 - Published REDUCE-IT echocardiographic substudy showing icosapent ethyl effects on ventricular function in high-risk patients
- Zeitouni et al., 2020 - Demonstrated colchicine's anti-inflammatory effects in patients post-myocardial infarction from COLCOT trial
- Kwong et al., 2018 - Linked influenza infection to acute myocardial infarction risk in case-series crossover design, establishing infection as trigger
- Packer et al., 2019 - Analyzed EMPEROR trials data on empagliflozin in heart failure outcomes, showing benefit across ejection fractions
Preparing a JAMA Cardiology Submission?
Get pre-submission feedback from reviewers who've published in JAMA Cardiology and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? See Expert Review Options
Primary Fields
Browse by Field
Related Journal Guides
- Publishing in Circulation
- Publishing in European Heart Journal
- Publishing in Circulation Research
- Publishing in Journal of the American College of Cardiology
- Publishing in RNA
Latest Journal-Specific Guides
- Submission guideJAMA Cardiology Submission GuideA practical JAMA Cardiology submission guide focused on clinical importance, broad-readership fit, and package readiness before upload.
- Journal assessmentIs JAMA Cardiology a Good Journal? The JAMA Network's Cardiovascular TitleJAMA Cardiology (IF 14.1) is the JAMA Network's cardiovascular journal. Here's when it's the right target, how the JAMA transfer pipeline works, and how it compares to JACC, Circulation, and EHJ.
- Desk rejectionHow to Avoid Desk Rejection at JAMA CardiologyPractical guidance on how to avoid desk rejection at JAMA Cardiology, including what editors screen for first and where strong papers usually fail.
- Review timelineJAMA Cardiology Review Time: What Authors Can Actually ExpectJAMA Cardiology is unusually transparent about how quickly it triages papers. The real question is whether the manuscript is broad and practice-relevant enough to survive that screen.
More Guides for This Journal
- Impact factorJAMA Cardiology Impact Factor 2026: 14.1, Q1, Rank 7/230JAMA Cardiology impact factor is 14.1 with a 5-year JIF of 15.6. See the rank, trend, and what that means before submission.
- Submission processJAMA Cardiology Submission Process: Steps & Timeline (2026)A practical JAMA Cardiology process guide covering what happens after upload, early editorial triage, and where papers get redirected.
- Manuscript prepJAMA Cardiology Cover Letter: What Editors Actually Need to SeeJAMA Cardiology cover letters work when they show a broad cardiology consequence quickly and avoid sounding like a prestige pitch for a narrower paper.
- Publishing guideJAMA Cardiology Formatting Requirements: The Submission Package GuideJAMA Cardiology formatting is not mainly stylistic. It is a disciplined JAMA Network package: 3000-word research paper, structured abstract, Key Points, reporting checklist, data sharing, and clean display-item limits.
Ready to submit to JAMA Cardiology?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what JAMA Cardiology editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to JAMA Cardiology. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to JAMA Cardiology reviewers.
Reference library
Compare JAMA Cardiology with the broader publishing context
This journal guide is the best starting point for JAMA Cardiology. The reference library covers the surrounding questions authors usually ask next: whether the package is ready, what drives desk rejection, how neighboring journals compare, and what the submission constraints look like across the field.
Checklist system / operational asset
Elite Submission Checklist
A flagship pre-submission checklist that turns journal-fit, desk-reject, and package-quality lessons into one operational final-pass audit.
Flagship report / decision support
Desk Rejection Report
A canonical desk-rejection report that organizes the most common editorial failure modes, what they look like, and how to prevent them.
Dataset / reference hub
Journal Intelligence Dataset
A canonical journal dataset that combines selectivity posture, review timing, submission requirements, and Manusights fit signals in one citeable reference asset.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Need field-expert depth? See Expert Review Options